Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks

Not Applicable

Recruiting

• Conditions: Diabetic Neuropathy

• Registration Number: NCT06452914
• Lead Sponsor: Endocrine Research Solutions

Brief Summary

Distal symmetric polyneuropathy, also known as diabetic neuropathy, is the most common neurological complication of diabetes and a main cause of morbidity. The condition leads to gradual loss of function of the longest nerve fibers that limits function and decreases quality of life. Symptoms present distally and symmetrically in toes and feet. Symptoms of the neurologic disability include sensory loss, risk of foot ulcers and limb amputations and pain. The condition is not generally considered reversible, and condition management aims to slow progression and prevent complications.

According to estimates from the International Diabetes Federation, diabetic neuropathy affected approximately 425 million people in 2017, with projections indicating a rise to 628 million by 2045. Despite the high prevalence of this condition, it is commonly misdiagnosed and has limited treatment options. There are multiple phenotypes of diabetic neuropathy, with the most common form being distal symmetric sensorimotor polyneuropathy, which is what we will be focusing on in this study.

The proposed study seeks to evaluate the effectiveness of a non-compressive therapeutic socks throughout a 12-week course of rehabilitation for managing distal symmetric polyneuropathy. Outcome measures will be collected at standard intervals and compared with pre-treatment measures to evaluate effectiveness of treatment.

Detailed Description

Treatments for diabetic neuropathy includes a systematic, stepwise approach that entails glycemic control and control of metabolic syndrome, symptomatic treatment of pain, and counseling on foot care and safety measures.

Unlike compression products, the semiconductor embedded socks increase blood circulation through activation of the elements with heat of the body, and releases mid and far infrared waves as well as negative ions. Both infrared waves and negative ions are biologically active and mediate inflammatory and pain pathways in the body. The technology has also been shown to increase blood speed and blood flow. The technology has also been shown to:

* Increase blood flow and velocity

* Reduce osteoarthritis pain

* Reduce effusion post total knee arthroplasty

* Improve chondrogenic differentiation in vitro

* Improve muscle recovery

* Increase circulation by up to 22% at rest

* Improve functional outcomes

The benefits of the Infrared Wave and Negative Ion therapy include:

* Inhibition of Cox-2 and Prostaglandins in the lipopolysaccharide (LPS)-moderated pain pathway

* Up-regulation of heat shock protein

* Mediated Nitric oxide production

* Increased activity of voltage-gated ion channels

* Increased activity of mechanosensitive ion channels

* Polarization of cell surface membranes

* Protecting muscle damage

* Scavenging of Reactive Oxygen Species (ROS)

* Improved thermoregulation

To date, studies have shown that the semiconductor embedded fabric increase circulation by up to 22% at rest, and have shown powerful results in reducing inflammation, swelling, improving range of motion in the knee post-surgery, and providing pain relief.

The semiconductor embedded fabric emits mid-level and far infrared waves and negative ions. Delivery of infrared waves and negative ions to the tissue increases blood flow, facilitates the anti-inflammatory nitric oxide (NO) cascade by accelerating the binding of calcium (Ca2+) to calmodulin (CaM). NO provides several healing factors to the body as a vasodilator, increasing blood and lymphatic flow. Additionally, NO down-regulates interleukin-1 beta (IL1β) and inducible nitric oxide synthase (iNOS) in certain cell types, which leads to reduced cyclooxygenase-2 (COX-2) and prostaglandins - molecules responsible for causing inflammation and pain. Unlike other systemic COX-2 inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), targeted infrared and negative ion therapy stimulate localized reaction pathways, thereby reducing pain and inflammation.

This study seeks to identify patient reported outcomes for management of Diabetic Neuropathy with semiconductor embedded fabric in the affected area.

Study Timeline

• Study First Submitted: 2024-05-30
• Study First Submitted QC: 2024-06-06
• Study Start: 2024-06-11
• Study First Posted: 2024-06-11
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-24
• Last Update Posted: 2025-02-25
• Primary Completion: 2025-06
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Patients diagnosed with mild to moderate Diabetic Neuropathy with a score between 2 and 7 out of 10 on the MNSI upon clinical examination and assessment.
• Patients reporting symptoms of Diabetic Neuropathy
• Patients age 18-79
• Patients who are willing and able to adhere to follow-up schedule and protocol guidelines
• Patients who are willing and able to sign corresponding research subject consent form

Exclusion Criteria

• Patient has a history of neurodegenerative conditions, including multiple sclerosis or Parkinson's disease
• Patient has chronic pain conditions unrelated to diabetic neuropathy, including spinal stenosis, low back pain, and sciatica
• Patient has auto-immune or auto-inflammatory diseases other than Diabetic Neuropathy, including Multiple Sclerosis or Lyme Disease
• Patient has experienced a stroke
• Patient has any type of paralysis
• Patients with a score less than 2 and greater than 7 out of 10 on the MNSI upon clinical examination and assessment
• Patient has severe peripheral artery disease (with an ankle brachial index of <0.7)
• Patient has chronic venous insufficiency (greater than stage 4)
• Patient has used tobacco within the last 90 days
• Patient has an open wound at the area of application
• Patient has started a new medication for diabetic neuropathy symptoms within the past 90 days
• Patient is not within the ages of 18-79
• Patient is unwilling or unable to sign the corresponding research subject consent form
• Patient meets any other criteria or has any other condition that, in the opinion of the investigator, would prevent them from completing the study or that, in the opinion of the investigator, would confound study results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Improved patient function as determined by pre-treatment and post-treatment Patient Specific Lower Extremity Functional Scale (LEFS), Michigan Neuropathy Screening Instrument (MNSI), and Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN) compared	12 Weeks	LEFS consists of 20 items, each scored on a 5-point scale (0 = extreme difficulty, 4 = no difficulty).; Scoring: The maximum score is 80, with higher scores indicating better function. A lower score suggests greater disability or difficulty in performing daily activities.; The MNSI has two parts- Part A: Self-administered questionnaire with 15 items about symptoms related to neuropathy. Scoring is based on the presence or absence of symptoms, with a higher score indicating more symptoms.; Part B: Physical examination conducted by a healthcare professional that includes inspection of the feet and assessment of reflexes and sensation. A higher score indicates more severe neuropathy.; QOL-DN encompasses multiple domains such as physical health, emotional well-being, social participation, and specific neurological symptoms.; Scoring: Each domain is scored individually, and a composite score can be derived, from -4 to 136. Higher scores indicate better quality of life.

Secondary Outcome Measures

Name	Time	Method
Compliance with device usage throughout the study, reported weekly.	12 Weeks	Device usage will be tracked with a device usage log that the patient completes based on hours the device is worn every day, to self-report compliance.
Reduction in symptom severity upon physical examination and improvement in quantitative sensory testing measures from pre-treatment measures compared to placebo.	12 Weeks	A series of tests are performed. Through the use of a tuning fork placed on the foot, if the patient no longer feels vibration after 8 seconds but does feel it for longer than 8 seconds when placed on the hand, severity of neuropathy can be determined. Through the use of a reflex hammer, tapping the ankle determines the presence or absence of ankle reflexes. Mono-filament testing, where after a series of touches in specific locations on the bottom of the foot, the presence or absence of sensation can be quantified.
Reduction in pain as determined by pre-treatment and post-treatment Numeric Pain Rating Scale or Visual Analog Scale (VAS) compared to placebo.	12 Weeks	Reduction in pain as measured by Visual Analog Scale from 1 to 10, with 1 being mild and 10 being severe.
Improvement in tissue oxygenation of the affected foot/feet as determined by clinically captured images with the non-invasive Kent Imaging device and pulse oximeter compared to placebo.	12 Weeks	Improvement in tissue oxygenation of the affected foot/feet as determined by clinically captured images with the non-invasive Kent Imaging device and pulse oximeter compared to placebo.

Trial Locations

Locations (1)

Endocrine Research Solutions, Inc.; 🇺🇸 Roswell, Georgia, United States